Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocort proof-of-concept study in peripheral artery disease
2012-000543-27Phase 2Active
- Sponsor
- AMC Health
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of hydrocortisone in arteriosclerosis obliterans, atherosclerosis and vasculitis (3 arms), sponsored by AMC Health. Primary endpoint: Quantity of PEG liposomes in atherosclerotic plaque and/or macrophages. Started Feb 2012; status: active.
02
Drugs
hydrocortisone
03
Conditions
arteriosclerosis obliteransatherosclerosisvasculitis
Beyond the preview
Go deeper on 2012-000543-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000543-27.